Li Junmin
李军民
Chief Physician, Doctoral Supervisor, Deputy Director of Hematology, and Deputy Director of the Shanghai Institute of Hematology
Hematologic malignancies including acute promyelocytic leukemia, acute myeloid leukemia, lymphoma, and multiple myeloma, with additional work in hematologic immunology and cellular immunotherapy(血液系统恶性肿瘤诊疗，重点包括急性早幼粒细胞白血病、急性髓系白血病、淋巴瘤、多发性骨髓瘤，并涉及血液免疫疾病与细胞免疫治疗)
1,780+ career cases
(haodf.com)Leadership & Positions
- Deputy Director, Department of Hematology, Ruijin Hospital
- Deputy Director, Shanghai Institute of Hematology
- Vice President, Ruijin Hospital Wuxi Branch
- Director, Difficult Case Consultation Center, Ruijin Hospital
- Chair, Hematologic Oncology Professional Committee, Shanghai Anti-Cancer Association
- Vice Chair, Hematology Branch, Shanghai Medical Association
- Committee Member, Hematology Branch, Chinese Medical Association
Medical School
Suzhou Medical College (1987)
Graduate
Master's degree in Hematology, Shanghai Second Medical University
Fellowships & Training
Paris Institute of Hematology and Vascular Diseases — Advanced study in hematology (France)
The University of Texas MD Anderson Cancer Center — Advanced study in hematologic oncology (United States)
Notable Publications
Cellular hierarchy insights reveal leukemic stem-like cells and early death risk in acute promyelocytic leukemia.
Nature Communications (2024) — co-author
PubMed/DOIInterplay between hypertriglyceridemia and acute promyelocytic leukemia mediated by the cooperation of peroxisome proliferator-activated receptor-α with the PML/RAR α fusion protein on super-enhancers.
Haematologica (2022) — co-author
PubMed/DOIIntegration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia.
Clinical Cancer Research (2021) — co-author
PubMed/DOIPioneering Contributions
- As a senior Ruijin Hospital hematologist and deputy director of the Shanghai Institute of Hematology, Li Junmin is part of the institutional lineage that developed and extended the internationally recognized APL treatment approach known as the 'Shanghai Protocol'.
- His publication record shows sustained contributions to modern APL work at Ruijin, including prognostic modeling, metabolic biology, leukemic stem-like cell analysis, and early-death risk stratification in acute promyelocytic leukemia.
- Secondary professional profiles state that he participated in drafting Chinese clinical treatment guidelines for acute promyelocytic leukemia, linking his work to the translation of Ruijin's APL experience into broader clinical practice.
Sources — Li Junmin
- https://www.haodf.com/doctor/13159.html—Identity verification, current Ruijin affiliation, titles, specialty focus, and cumulative patient-help count(accessed Apr 16, 2026)
- https://pubmed.ncbi.nlm.nih.gov/38365836/—Publication verification and APL early-death-risk research contribution(accessed Apr 16, 2026)
- https://pubmed.ncbi.nlm.nih.gov/35546300/—Publication verification and APL metabolic biology contribution(accessed Apr 16, 2026)
- https://pubmed.ncbi.nlm.nih.gov/33893160/—Publication verification and APL prognostic modeling contribution(accessed Apr 16, 2026)
- https://www.rjh.com.cn/2018RJPortal/main/yyjs/rjgk/index.shtml—Ruijin Hospital context, hematology strength, and Shanghai Protocol institutional background(accessed Apr 16, 2026)
- https://english.shanghai.gov.cn/en-Hospitals/20241014/c1033495f786489db7adbad3a6...—Official English hospital name confirmation(accessed Apr 16, 2026)
Request a case review with Li Junmin
Li Junmin practices at The Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine in Shanghai.
Request Case Review